MedTrace Logo

Long-term Follow-up of Patients Included in the EYE-TAR(MA) Study.

NCT05254873 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 7

Last updated 2023-12-15

No results posted yet for this study

Summary

EYE-TAR(MA)-Follow-Up is a non-interventionel, long-term follow-up study in subjects who participated to the study referred as EYE-TAR(MA) (NCT04730440)

EYE-TAR(MA)-Follow-Up aims to evaluate the long-term impacts of the Training of Affect Recognition TAR (an emotion recognition rehabilitation program), on social cognition abilities, evolve gaze strategies, behavioral disorders, and the caregiver's burden in Alzheimer's disease (AD).

Subjects who completed EYE-TAR(MA) study, and who have signed informed consent for this follow-up, will be eligible to enroll. They will attend one visit two years post EYE-TAR(MA) study intervention (intervention was TAR, or a "classic" cognitive stimulation program) to undergo the following evaluation: Eye-tracking recording during Ekman Faces task, Mini Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI), Zarit scale (completed by caregiver).

Conditions

  • Alzheimer's Dementia (AD)
  • Family Caregivers

Interventions

OTHER

Long term follow-up

Long term follow-up for patient who completed the EYE-TAR(MA) study.

Sponsors & Collaborators

  • Centre Hospitalier Princesse Grace

    collaborator OTHER

  • Association de Recherche Bibliographique pour les Neurosciences

    lead OTHER

Principal Investigators

  • Sandrine LOUCHART DE LA CHAPELLE, MD-PhD · Centre Mémoire, Centre de Gérontologie Clinique RAINIER III, Princess Grace Hospital, Monaco

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-21
Primary Completion
2022-04-11
Completion
2022-04-11

Countries

  • Monaco

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05254873 on ClinicalTrials.gov